Search

Displaying results 3441 - 3450 of 10000 in total
  1. Drug

    Ondelopran

    go.drugbank.com/drugs/DB12585
    Investigational

    Ondelopran has been used in trials studying the treatment of Alcohol Dependence.

    Categories: Drugs Used in Addictive Disorders, Drugs Used in Alcohol Dependence
  2. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. … Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors).

  3. Drug

    Estazolam

    go.drugbank.com/drugs/DB01215
    ApprovedIllicitInvestigational

    It has been shown in some cases to be more potent than diazepam or nitrazepam.

  4. Drug

    Sizofiran

    go.drugbank.com/drugs/DB13128
    Investigational

    It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach. Sizofiran has been used in trials studying the treatment of Cervical Cancer.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. … Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1).

  6. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263] … The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016].

  7. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    Aficamten is a cardiac myosin inhibitor. … [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and

    Synonyms: (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide, (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide
  8. Drug

    Frangula purshiana bark

    go.drugbank.com/drugs/DB15478
    Approved

    Mixtures: Cholasyn II
  9. Drug

    Trehalose

    go.drugbank.com/drugs/DB12310
    Investigational

    Cabaletta has been used in trials studying the treatment of Oculopharyngeal Muscular Dystrophy.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved